Free Trial
NASDAQ:FBRX

Forte Biosciences Q4 2023 Earnings Report

Forte Biosciences logo
$6.32 -0.34 (-5.11%)
Closing price 03:59 PM Eastern
Extended Trading
$6.42 +0.11 (+1.66%)
As of 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences EPS Results

Actual EPS
-$0.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Forte Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Forte Biosciences Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 18, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Forte Biosciences' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Forte Biosciences Earnings Headlines

Forte Biosciences price target lowered to $61 from $64 at Chardan
REVEALED: Elon’s Secret Master Plan “AGENDA X”
REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secret. Now, leaked computer code confirms Elon is moments away from launching a revolutionary financial technology… And Silicon Valley insider Jeff Brown says it could hand early investors who missed Tesla, "the ultimate second chance" to get rich.
Forte Biosciences (FBRX) Gets a Buy from TD Cowen
Forte Biosciences files $300M mixed securities shelf
See More Forte Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email.

About Forte Biosciences

Forte Biosciences (NASDAQ:FBRX) operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

View Forte Biosciences Profile

More Earnings Resources from MarketBeat